Travere Therapeutics (TVTX) Accounts Payables (2011 - 2026)

Travere Therapeutics' Accounts Payables history runs 16 years deep, the most recent figure standing at $12.9 million for Q1 2026.

• Quarterly Accounts Payables fell 16.01% year-over-year to $12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.9 million (down 16.01% YoY) and the FY2025 annual result came in at $24.8 million, up 5.38% from the prior year.
• Accounts Payables was $12.9 million for Q1 2026 at Travere Therapeutics, down from $24.8 million in the prior quarter.
• Across five years, Accounts Payables topped out at $41.7 million in Q4 2023 and bottomed at $11.8 million in Q2 2022.
• A 5-year average of $20.3 million and a median of $18.4 million in 2022 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 141.04% — and 2024, when it plunged 43.53%.
• Travere Therapeutics' Accounts Payables stood at $17.3 million in 2022, then soared by 141.04% to $41.7 million in 2023, then plunged by 43.53% to $23.5 million in 2024, then gained by 5.38% to $24.8 million in 2025, then sank by 47.94% to $12.9 million in 2026.
• Business Quant data shows TVTX's Accounts Payables at $12.9 million in Q1 2026, $24.8 million in Q4 2025, and $18.2 million in Q3 2025.